Apyx Medical (FRA:BOV) PE Ratio: At Loss (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BOV Apyx Medical Corp FRA:BOV
72 GF Score
Price €2.56
GF Value €1.85
! 2 Warning Signs
View Full Analysis

What is Apyx Medical PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-18), Apyx Medical's share price is €2.56. Apyx Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.17. Therefore, Apyx Medical's PE Ratio for today is At Loss.

During the past 13 years, Apyx Medical's highest PE Ratio was 4.90. The lowest was 0.00. And the median was 3.76.

Apyx Medical's EPS (Diluted) for the three months ended in Jun. 2026 was €-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.17.

As of today (2026-08-18), Apyx Medical's share price is €2.56. Apyx Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.17. Therefore, Apyx Medical's PE Ratio without NRI ratio for today is At Loss.

Apyx Medical's EPS without NRI for the three months ended in Jun. 2026 was €-0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.17.

During the past 3 years, the average EPS without NRI Growth Rate was 26.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -7.80% per year.

During the past 13 years, Apyx Medical's highest 3-Year average EPS without NRI Growth Rate was 71.00% per year. The lowest was -80.60% per year. And the median was -0.20% per year.

Apyx Medical's EPS (Basic) for the three months ended in Jun. 2026 was €-0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.17.

Back to Basics: PE Ratio


Apyx Medical  (FRA:BOV) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Apyx Medical PE Ratio Related Terms


Apyx Medical PE Ratio Historical Data

* Premium members only.

The historical data trend for Apyx Medical's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apyx Medical PE Ratio Chart

Apyx Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Apyx Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

FRA:BOV vs INGN, QSI, QTRX: PE Ratio Comparison

For the Medical Devices subindustry, Apyx Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apyx Medical PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Apyx Medical's PE Ratio falls into.


FRA:BOV
72GF Score
Apyx Medical Corp FRA:BOV
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apyx Medical PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Apyx Medical's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=2.56/-0.173
=-14.8(At Loss)

Apyx Medical's Share Price of today is €2.56.
Apyx Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.17.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is Apyx Medical (FRA:BOV) Overvalued in 2026?

Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued. The current stock price of €2.56 is trading 38.4% above its estimated GF Value™ of €1.85.

Key valuation signals for FRA:BOV:

  • PE Ratio: At Loss
  • GF Value™: €1.85 vs. price of €2.56 (38.4% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apyx Medical Business Description

Other Exchanges APYX:USA
Address 5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score

Get the complete analysis for FRA:BOV

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price
€1.85
GF Value